Lung Cancer Clinical Trial
Official title:
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study
Verified date | October 2020 |
Source | CTI BioPharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV,
or recurrent non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel
plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have stage
IIIB, stage IV, or recurrent non-small cell lung cancer.
Status | Terminated |
Enrollment | 0 |
Est. completion date | October 2004 |
Est. primary completion date | October 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting 1 of the following criteria: - Locally advanced or recurrent disease previously treated with radiotherapy and/or surgery - Stage IIIB and not a candidate for combined modality therapy - Stage IV - No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology - Cytological diagnosis must be based on the following: - No cellular diagnosis by sputum cytology alone - Cytologic specimens obtained from brushings, washings, or needle aspiration of a defined lesion or pleural effusion are acceptable - Measurable or nonmeasurable disease - Brain metastases allowed provided patient received prior standard antitumor therapy for CNS metastases (e.g., whole brain radiotherapy, stereotactic radioablation, or surgery) and the following conditions are met: - Neurologic function stable for at least 2 weeks before study entry - Off steroid therapy or on a tapering regimen - Recovered from prior therapy PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 2 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than upper limit of normal (ULN) - SGOT/SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases present) - Alkaline phosphatase no greater than 2.5 times ULN (except for laboratory documentation that demonstrates bone origin) Renal - Creatinine no greater than 1.5 times ULN Cardiovascular - No unstable angina - No myocardial infarction within the past 6 months - Cardiac conduction abnormalities (e.g., bundle branch block or heart block) allowed provided cardiac status has been stable for at least 6 months prior to study entry Neurologic - See Disease Characteristics - No neuropathy greater than grade 1 - No evidence of unstable neurological symptoms within the past 4 weeks (2 weeks for neurological symptoms due to brain metastases) Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No intolerance to excipients of polyglutamate paclitaxel (e.g., poly-L-glutamic acid, poloxamer 188, dibasic sodium phosphate, or monobasic sodium hydroxide) - No clinically significant active infection - No other concurrent primary malignancy except carcinoma in situ or nonmelanoma skin cancer - No other unstable medical conditions - No circumstance that would preclude study completion or follow-up PRIOR CONCURRENT THERAPY: Biologic therapy - No prior systemic biologic agent for lung cancer Chemotherapy - See Disease Characteristics - No prior systemic therapy for lung cancer including radiosensitizing agents Endocrine therapy - See Disease Characteristics Radiotherapy - See Disease Characteristics - No concurrent radiotherapy Surgery - See Disease Characteristics - Recovered from prior major surgery Other - More than 12 weeks since prior participation in any research study or treatment with investigational drugs - Recovered from prior investigational therapy or stable for 4 weeks before study treatment - No other concurrent investigational drugs - No other concurrent systemic antitumor therapy - No concurrent amifostine - Concurrent bisphosphonates allowed |
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
United States | Hematology and Oncology Associates of Alabama | Birmingham | Alabama |
United States | Highline Medical Oncology | Burien | Washington |
United States | Gabrail Cancer Center - Canton Office | Canton | Ohio |
United States | Charleston Cancer Center | Charleston | South Carolina |
United States | Clarksville Regional Hematology/Oncology Group | Clarksville | Tennessee |
United States | Family Cancer Center | Collierville | Tennessee |
United States | Columbia Comprehensive Cancer Care Clinic | Columbia | Missouri |
United States | Synergy Hematology/Oncology Medical Associates | Encino | California |
United States | Hattiesburg Clinic, P.A. | Hattiesburg | Mississippi |
United States | Clinical Research Consultants, Inc | Hoover | Alabama |
United States | University of Texas - MD Anderson Cancer Center | Houston | Texas |
United States | New Hope Cancer Centers | Hudson | Florida |
United States | Silver Cross Hospital | Joliet | Illinois |
United States | Las Vegas Cancer Center | Las Vegas | Nevada |
United States | Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia |
United States | Omni Healthcare, PA | Melbourne | Florida |
United States | Holy Cross Providence Cancer Center | Mission Hills | California |
United States | Clinical Trials and Research Associates, Incorporated | Montebello | California |
United States | MetCare Oncology | Ormond Beach | Florida |
United States | Kentucky Cancer Clinic | Pikeville | Kentucky |
United States | Hematology Oncology Associates of theTreasure Coast - Port St. Lucie | Port Saint Lucie | Florida |
United States | Rainier Oncology | Puyallup | Washington |
United States | Virginia Oncology Care P.C. | Richlands | Virginia |
United States | Bond Clinic | Rolla | Missouri |
United States | Cancer Therapy and Research Center | San Antonio | Texas |
United States | Gross Point Medical Center | Skokie | Illinois |
United States | Hematology Oncology, P.C. | Stamford | Connecticut |
United States | Summit Medical Group, P.A. | Summit | New Jersey |
United States | Santee Hematology Oncology | Sumter | South Carolina |
United States | California Hematology/Oncology Medical Group | Torrance | California |
United States | Georgia Cancer Specialists - Tucker | Tucker | Georgia |
United States | Arizona Clinical Research Center | Tucson | Arizona |
United States | Oklahoma Oncology, Inc. - St. John Campus | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
CTI BioPharma |
United States, Canada,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|